Surgeons as gatekeepers
Rates of referral for presurgical multidisciplinary assessment in BC
Barbara Poole, MPA; Thomas G. Ehlen, MD, PhD; Noelle L. Davis, MD

Emotional distress screening in Canadian cancer care
How and where is it being done?
Andrea Vodermaier, PhD and Wolfgang Linden, PhD

Review of important clinical trials with commentaries by Canadian experts
The 44th Annual Meeting of the American Society of Clinical Oncology
KRAS as a predictive marker in metastatic colorectal cancer
Howard J. Lim, MD, PhD, FRCPC and Sharlene Gill, MD, MPH, FACP, FRCPC
Microsatellite instability and adjuvant therapy for Stage II colon cancer
Sharlene Gill, MD, MPH, FACP, FRCPC
A prognostic test for early Stage IB–II NSCLC
Gwyn Bebb, BMBCh, PhD, FRCPC
Cetuximab in advanced NSCLC
Natasha B. Leighl, MD, MMSc, FRCPC
Targeted therapies in metastatic breast cancer
Sunil Verma, MD, MSEd, FRCPC and Danny Robson, MD, FRCPC
Hormonal therapy and targeted agents in metastatic breast cancer
Debjani Grenier, MD, FRCPC

Cover photo: Colon cancer cells • steve Gschmeissner / SPL / PUBLIPHOTO

Trastuzumab in advanced breast cancer
Joseph Ragaz, MD, FRCPC
First-line treatment of metastatic renal cell cancer
Sebastien J. Hotte, MD, MSc, FRCPC
Second-line treatment of metastatic renal cell cancer
Anil Kapoor, MD, FRCSC
Stage I testicular seminoma
Christian Kollmansberger, MD, FRCPC and Padraig Warde, MB, CHB, BAO, BA, FRCPC

EGFR inhibitors and availability of KRAS testing for metastatic colorectal cancer in Canada
Jean A. Maroun, MD, FRCPC, FRCP (London)

The buck stops here: oncologists’ role in managing expectations
Stephan Larsson, Mb, ChB (Birm), MRCP(UK), FRCR, FRCPC

Professional meetings roster
Your calendar dates for essential conferences and symposia

New drugs and indications
A review of recent cancer therapy
approvals in Canada and the US